These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 26230381)
1. Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy. Mirzakhani H; van Dormolen J; van der Weide K; Guchelaar HJ; van Noorden MS; Swen J Pharmacogenet Genomics; 2015 Oct; 25(10):515-7. PubMed ID: 26230381 [TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126 [TBL] [Abstract][Full Text] [Related]
4. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748 [TBL] [Abstract][Full Text] [Related]
6. Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors. Gressier F; Verstuyft C; Hardy P; Becquemont L; Corruble E J Neural Transm (Vienna); 2015 Jan; 122(1):35-42. PubMed ID: 25047911 [TBL] [Abstract][Full Text] [Related]
7. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553 [TBL] [Abstract][Full Text] [Related]
8. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and the pharmacological management of depression. Krauter RR; Cook SS Nurse Pract; 2011 Oct; 36(10):14-21; quiz 21-2. PubMed ID: 21937968 [TBL] [Abstract][Full Text] [Related]
10. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy]. Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673 [TBL] [Abstract][Full Text] [Related]
11. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762 [TBL] [Abstract][Full Text] [Related]
12. CYP2D6 poor metabolizer genotype and smoking predict severe postoperative pain in female patients on arrival to the recovery room. Yang Z; Yang Z; Arheart KL; Morris R; Zhang Y; Rodriguez Y; Song C; Gitlin MC; Candiotti KA Pain Med; 2012 Apr; 13(4):604-9. PubMed ID: 22497725 [TBL] [Abstract][Full Text] [Related]
13. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Gagné GG; Furman MJ; Carpenter LL; Price LH Am J Psychiatry; 2000 Dec; 157(12):1960-5. PubMed ID: 11097961 [TBL] [Abstract][Full Text] [Related]
15. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Laika B; Leucht S; Heres S; Steimer W Pharmacogenomics J; 2009 Dec; 9(6):395-403. PubMed ID: 19451914 [TBL] [Abstract][Full Text] [Related]
19. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051 [TBL] [Abstract][Full Text] [Related]
20. The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Müller DJ; Brandl EJ; Hwang R; Tiwari AK; Sturgess JE; Zai CC; Lieberman JA; Kennedy JL; Richter MA Genet Test Mol Biomarkers; 2012 Aug; 16(8):897-903. PubMed ID: 22775532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]